STRO

Sutro Biopharma, Inc.

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$9.59

Price (1 Year)

$40.24 $8.66

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %0 / %30
Non-compliant assets / Total market cap %48.5 / %30
Non-compliant revenue / Total income %12.1 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+.

Website

Analysis (Turkish): STRO Hissesi Caiz mi, Helal mi? Sutro Biopharma, Inc. Katılım Analizi